A leading coronavirus vaccine candidate developed by Pfizer and BioNTech will be submitted for regulatory approval “within days,” the companies announced Wednesday, after their final analysis suggested the drug was even more effective than previously thought.
The U.S. pharma giant and its German partner said their Phase 3 trial was now complete and that it found the vaccine was 95 percent effective at preventing symptomatic Covid-19 — up from the 90 percent announced last week.
(Via Hot Air Headlines) That number represents over forty thousand adults in that stage. Side effects were remarkably mild: a small percentage reported fatigue or headaches. …I can live with either, thanks. Pzifer says it can get 50 million doses out by the end of the year and 1.3 billion in 2021; if Moderna’s vaccine (which needs only standard refrigeration) also works out, we’re in a good position to have the coronavirus suddenly slam into a brick wall. Which would a no-fooling good thing to have.